Fluticasone furoate - Glucocorticoid receptor agonist intranasal corticosteroid

Allergic rhinitis is characterized by symptoms (e.g., frequent or repetitive sneezing, runny or congested nose, pruritus of the nose, eyes and throat) that are the result of complex allergen-driven mucosal inflammation mediated by resident/infiltrating inflammatory cells, inflammatory mediators and cytokines. Thus, strategies for the treatment of allergic rhinitis have focused on targeting various levels of the inflammatory cascade. Intranasal corticosteroids are becoming an increasingly popular first-line therapy for allergic rhinitis. They target the allergic inflammation which contributes to the late-stage symptom of nasal congestion and they can be used prophylactically to prevent early-phase responses to allergens. Fluticasone furoate exhibits enhanced affinity for the glucocorticoid receptor, potent preclinical antiinflammatory activity and efficacy in patients with seasonal allergic rhinitis. Fluticasone furoate has been submitted for regulatory approval for the treatment of allergic rhinitis and is undergoing phase 11 development for asthma and chronic obstructive pulmonary disease (COPD).